As filed with the Securities and Exchange
Commission on May 16, 2023
Registration
No. 333-271328
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
CADRE HOLDINGS, INC.
(Exact name of registrant as specified in charter)
| Delaware |
|
38-3873146 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
13386 International Pkwy
Jacksonville, FL 32218
(904) 741-5400
(Address, including zip code and telephone number,
including area code, of registrant’s principal executive offices)
Warren B. Kanders
Chief Executive Officer
Cadre Holdings, Inc.
13386 International Pkwy
Jacksonville, FL 32218
(904) 741-5400
(Name, address, including zip code and telephone
number, including area code, of agent for service of process)
Copy to:
Robert L. Lawrence, Esq.
Kane Kessler, P.C.
600 Third Avenue
35th Floor
New York, NY 10016
(212) 541-6222
Approximate Date of Commencement of Proposed
Sale to Public: From time to time after the effective date of this Registration Statement.
If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than the securities
offered only in connection with dividend or interest reinvestment plans, check the following box. x
If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant
to General Instruction I.D. or a post effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following. ¨
If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company”
in Rule 12b-2 of the Exchange Act:
Large accelerated filer ¨ Accelerated
filer x Non-accelerated filer ¨ Smaller
reporting company ¨ Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant
to said Section 8(a), may determine.
The information
in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed
with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it
is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION DATED
MAY 16, 2023.
PRELIMINARY PROSPECTUS
CADRE HOLDINGS, INC.
$300,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
3,000,000 Shares
Common Stock
Offered by the Selling Securityholders
This prospectus provides
a general description of securities of Cadre Holdings, Inc. (the “Company,” “Cadre,” “we,” “our,”
and “us”) that we may offer and the general manner in which we will offer them. We may offer, issue and sell, from time to
time, in one or more offerings and series, together or separately, shares of our common stock, shares of our preferred stock, debt securities,
or warrants up to an aggregate amount of $300,000,000.
Each time any of our securities
is offered using this prospectus, we and/or any of our selling securityholders, where applicable, will provide a prospectus supplement
and attach it to this prospectus. The applicable prospectus supplement will contain more specific information about the offering. The
applicable prospectus supplement will also contain information, where appropriate, about material United States federal income tax consequences
relating to, and any listing on a securities exchange of, the debt or equity securities covered by the prospectus supplement. The applicable
prospectus supplement may also add, update or change the information in this prospectus and will also describe the specific manner in
which we will offer such securities.
This prospectus may not
be used to offer or sell securities without a prospectus supplement which includes a description of the method and terms of the offering.
You should carefully read
this prospectus and any accompanying prospectus supplement, together with the documents we incorporate by reference, before you invest
in our securities.
We may offer and sell the
securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly
to purchasers, or through a combination of these methods. In addition, the selling securityholders may offer and sell shares of our common
stock from time to time, together or separately. If any underwriters, dealers or agents are involved in the sale of any of the securities,
their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will
be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled “About
this Prospectus” and “Plan of Distribution” for more information. No securities may be sold without delivery of this
prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.
Our common stock is listed
on the New York Stock Exchange under the symbol “CDRE.” We will provide information in any applicable prospectus supplement
regarding any listing of securities other than shares of our common stock on any securities exchange.
Investing in our securities
involves a high degree of risks. Please refer to the “Risk Factors” section beginning on page 2 of this prospectus, “Item
1A – Risk Factors” of our most recent Annual Report on Form 10-K incorporated by reference herein, and under similar headings
in the applicable prospectus supplement and any other documents that are incorporated by reference herein or therein, for a description
of the risks you should consider when evaluating this investment.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2023.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part
of a “shelf” registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the “SEC”,
under the Securities Act of 1933, as amended, or the Securities Act, using a “shelf” registration process. Under this shelf
registration process, we may, from time to time, offer and/or sell, in one or more offerings and series, together or separately, shares
of our common stock, preferred stock, debt securities, or warrants up to an aggregate amount of $300,000,000 and the selling securityholders
to be named in a supplement to this prospectus may, from time to time, sell up to 3,000,000 shares of common stock from time to time
in one or more offerings as described in this prospectus. This prospectus only provides you with a general description of the securities
that we and the selling securityholders may offer. Each time that we or the selling securityholders offer and sell any securities, we
or the selling securityholders will provide a prospectus supplement and attach it to this prospectus that contains specific information
about the securities being offered and sold and the specific terms of that offering. The prospectus supplement will contain more specific
information about the terms of the securities and the offering. The applicable prospectus supplement will also contain information, where
appropriate, about material United States federal income tax consequences relating to, and any listing on a securities exchange of, the
debt or equity securities covered by the prospectus supplement. The prospectus supplement may also add, update or change information
contained in this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement
made by us or any of the selling securityholders in a prospectus supplement. This prospectus and the prospectus supplements provide you
with a general description of the Company and our securities as well as the securities to be sold by any of the selling securityholders.
Before purchasing any securities, you should read both this prospectus and any accompanying prospectus supplement together with the additional
information described under the headings “Where You Can Find More Information” and “Incorporation of Certain Information
by Reference.”
You should rely only on the
information contained in this prospectus or any prospectus supplement and those documents incorporated by reference in this prospectus
or any accompanying prospectus supplement. Neither we, nor the selling securityholders, have authorized anyone to provide you with information
that is in addition to, or different from, that contained in this prospectus or any accompanying prospectus supplement. If anyone provides
you with different or additional information, you should not rely on it. This prospectus may only be used where it is legal to sell these
securities, and neither we nor any of the selling securityholders have authorized anyone to make any representations in connection with
an offering other than those contained or incorporated by reference in this prospectus or any accompanying prospectus supplement. Neither
this prospectus nor any prospectus supplement is an offer to sell, or a solicitation of an offer to buy, in any state where the offer
or sale is prohibited. The information in this prospectus, any prospectus supplement or any document incorporated herein or therein by
reference is accurate as of the date contained on the cover of such documents. Neither the delivery of this prospectus or any prospectus
supplement, nor any sale made under this prospectus or any prospectus supplement will, under any circumstances, imply that the information
in this prospectus or any prospectus supplement is correct as of any date after the date of this prospectus or any such prospectus supplement.
References in this prospectus
to the “Company,” “Cadre,” “we,” “our,” and “us,” refer to Cadre Holdings,
Inc.
FORWARD-LOOKING STATEMENTS
Certain statements included
in this prospectus, any accompanying prospectus supplement and the documents incorporated by reference herein and therein are “forward-looking
statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and
beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions,
are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We
caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied
in the forward-looking statements.
Potential risks and uncertainties
that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied
by forward-looking statements in this prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein
include, but are not limited to, the availability of capital to satisfy our working capital requirements;
anticipated trends and challenges in our business and the markets in which we operate; our
ability to anticipate market needs or develop new or enhanced products to meet those needs; our expectations regarding market acceptance
of our products; the success of competing products by others that are or become available in the markets in which we sell our products;
the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection
with brand damaging events and/or public perception; changes in political, economic or regulatory conditions generally and in the markets
in which we operate; the impact of political unrest, natural disasters or other crises, terrorist acts, acts of war and/or military
operations, including, without limitation, the conflict between Russia and Ukraine; our ability
to maintain or broaden our business relationships and develop new relationships with strategic alliances, suppliers, customers, distributors,
or otherwise; our ability to retain and attract senior management and other key employees; our ability to quickly and effectively respond
to new technological developments; the effect of an outbreak of disease or similar public health threat, such as the COVID-19 pandemic,
on the Company’s business; logistical challenges related to supply chain disruptions and delays; the impact of inflationary
pressures and our ability to mitigate such impacts with pricing and productivity; the possibility
that the Company may be adversely affected by other political, economic, business, and/or competitive factors; the ability of our information
technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers,
malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade
our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems;
our ability to protect our trade secrets or other proprietary rights and operate without infringing upon the proprietary rights of others
and prevent others from infringing on the proprietary rights of the Company; our ability to maintain a quarterly dividend; and
the increased expenses associated with being a public company and the related increased disclosure and reporting obligations; and any
material differences in the actual financial results of the Company’s past and future acquisitions as compared with the Company’s
expectation. More information on potential factors that could affect the Company’s financial results is included from time to time
in the Company’s public reports filed with the SEC, including the Company’s Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements included in this prospectus are based upon information available
to the Company as of the date of this prospectus, and speak only as the date hereof. We assume no obligation to update any forward-looking
statements to reflect events or circumstances after the date of this prospectus.
You should also read carefully
the factors described or referred to in the “Risk Factors” section of this prospectus, any accompanying prospectus supplement
and the documents incorporated by reference herein and therein, to better understand the risks and uncertainties inherent in our business
and underlying any forward-looking statements. Any forward-looking statements that we make in this prospectus, any accompanying prospectus
supplement and the documents incorporated by reference herein as well as other written or oral statements by us or our authorized officers
on our behalf, speak only as of the date of such statement, and we undertake no obligation to update such statements. Comparisons of results
for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed
as such, and should only be viewed as historical data.
THE COMPANY
Company Overview
For
over 55 years, we have been a global leader in the manufacturing and distribution of safety and survivability equipment for first
responders. Our equipment provides critical protection to allow its users to safely perform their duties and protect those around them
in hazardous or life-threatening situations. Through our dedication to superior quality, we establish a direct covenant with end users
that our products will perform and keep them safe when they are most needed. We sell a wide range of products including body armor, explosive
ordnance disposal equipment and duty gear through both direct and indirect channels. In addition, through our owned distribution, we serve
as a one-stop shop for first responders providing equipment we manufacture as well as third-party products including uniforms, optics,
boots, firearms and ammunition. The majority of our manufactured product offering is governed by rigorous safety standards and regulations.
Demand for our products is driven by technological advancement as well as recurring modernization and replacement cycles for the equipment
to maintain its efficiency, effective performance and regulatory compliance.
Market Overview
Our
target end user base includes domestic and international first responders such as state and local law enforcement, fire and rescue, explosive
ordnance disposal technicians, emergency medical technicians, fishing and wildlife enforcement and departments of corrections, as well
as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of
Justice, U.S. Department of Homeland Security, U.S. Department of Corrections and numerous foreign government agencies. We have a large
and diverse customer base, with no individual customer representing more than 10% of our total revenue for the year ended December 31,
2022.
The
market for safety and survivability equipment serving first responders focuses on providing a diverse set of protective and mission enhancing
products and solutions to our target end users. The market is driven by multiple factors including customer refresh cycles, the growing
number of personnel employed by first responder organizations, equipment replacement and modernization trends, greater emphasis on public
and first responders’ safety and demographic shifts.
Body
armor, explosive ordnance disposal equipment and duty gear comprise the core product areas in the safety and survivability equipment market,
and law enforcement personnel growth is a significant driver for our business. The U.S. Bureau of Labor Statistics projects the number
of law enforcement personnel in the U.S. to increase at a faster rate than broader labor market growth over the 10-year period from 2019
to 2029, or 5%, from 813,500 in 2019 to 854,200 in 2029. Demand for first responder safety and survivability equipment is also fueled
by increasing law enforcement budgets.
In
addition to the macro industry trends, each of these product segments experiences unique drivers in and of themselves. Increasing mandatory
body armor use and refresh policies, evolving technical standards and increases in tactical or special weapons and tactics (“SWAT”)
law enforcement personnel act as tailwinds to the body armor market. Meanwhile, the explosive ordnance disposal equipment market is driven
by the continued emergence of new global threats while duty gear is primarily driven by product use, firearms accessories (lights and
red-dot sights) and replacement cycles.
Our
management estimates the annual addressable market for soft body armor (including tactical soft armor) to be approximately $870 million.
We also estimate explosive ordnance disposal equipment to have an addressable market of approximately $245 million over the seven-to-ten
year life cycle of the products’ installed base. Finally, the annual addressable market for holsters for the global law enforcement
and military and consumer markets is estimated to be approximately $380 million.
The
international market is also poised for growth as foreign governments face increasingly complex safety challenges and seek to replace
legacy equipment. Additionally, we foresee the demand for safety and survivability equipment from overseas markets to increase due to
heightened awareness of the importance and effectiveness of such products as countries are exposed to new threats. Our management estimates
our addressable number of total law enforcement personnel outside the U.S. to be approximately 9.7 million, representing a substantial
market opportunity.
Our
management team believes that the safety and survivability equipment industry for first responders represents a stable and growing market
with long-term opportunities. Given our strong market standing, direct connection to the end users, extensive distribution network, long
history of innovations and high-quality standards, we believe we are well positioned to capitalize on the positive market dynamics.
Corporate Overview
Cadre
Holdings, Inc. was incorporated in the State of Delaware on April 12, 2012.
Our
principal executive offices are located at 13386 International Pkwy, Jacksonville, Florida 32218 and our telephone number is (904) 741-5400.
Our website address is www.cadre-holdings.com. The information on, or that may be accessed through, our website is not a part of this
prospectus (other than the documents that we file with the SEC that are expressly incorporated by reference into this prospectus) and
the inclusion of our website address in this prospectus is an inactive textual reference only. See “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference.”
RISK FACTORS
Investment
in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. Please carefully consider
the risk factors described in our periodic and current reports filed with the SEC, which are incorporated by reference in this prospectus,
as well as any risks that may be set forth in or incorporated by reference into the prospectus supplement relating to a specific security.
Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate
by reference in this prospectus or include in any applicable prospectus supplement. The risks and uncertainties we have described are
not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial
may also affect our business operations. The occurrence of any of these risks could materially affect our business, results of operations
or financial condition and cause the value of our securities to decline. You could lose all or part of your investment.
USE OF PROCEEDS
The
use of proceeds from the sale of our securities will be specified in the applicable prospectus supplement.
Unless
stated otherwise in an accompanying prospectus supplement, we will use the net proceeds from the sale of securities described in this
prospectus for general corporate purposes.
When
a particular series of securities is offered, the accompanying prospectus supplement will set forth our intended use for the net proceeds
received from the sale of those securities. Pending application for specific purposes, the net proceeds may be temporarily invested in
marketable securities. The precise amounts and timing of the application of proceeds will depend upon our funding requirements and the
availability of other funds. Except as mentioned in any prospectus supplement, specific allocations of the proceeds to such purposes will
not have been made at the date of that prospectus supplement.
We will not receive any of
the proceeds from the sale of common stock being offered by any of the selling securityholders.
DESCRIPTION OF COMMON STOCK
The
following description of our common stock does not purport to be complete and is subject in all respects to applicable Delaware law and
qualified by reference to the provisions of our Amended and Restated Certificate of Incorporation, as amended (the “Certificate
of Incorporation”), and Amended and Restated Bylaws, as amended (the “Bylaws”). Copies of our Certificate of Incorporation
and Bylaws are incorporated by reference and will be sent to stockholders upon request. Please read “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference” to find out how you obtain a copy of those documents. We encourage
you to read carefully this prospectus, the Certificate of Incorporation, the Bylaws and the other documents we refer to herein for a more
complete understanding of the Company’s common stock.
Authorized and Outstanding Common Stock
Our
authorized capital stock consists of 200,000,000 shares of capital stock, par value $0.0001 per share, of which 190,000,000 shares are
common stock, par value $0.0001 per share (“Common Stock”), and 10,000,000 shares are undesignated preferred stock,
par value $0.0001 per share, and there are 37,586,031 shares of Common Stock outstanding
and no shares of preferred stock outstanding as of May 5, 2023. We are authorized to issue one class of common stock.
Voting Power
Except
as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders
of Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders
of Common Stock are entitled to one vote per share on matters to be voted on by stockholders. Generally,
all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of
the votes entitled to be cast by all stockholders present in person or represented by proxy, voting together as a single class.
Dividends
Holders
of Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by our Board of Directors (the
“Board”) in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits
or combinations of stock be declared or made on Common Stock unless the shares of Common Stock at the time outstanding are treated equally
and identically. We expect to continue pay a quarterly cash dividend of $0.08 per share, or $0.32
on an annualized basis, on our Common Stock for the foreseeable future, but we may elect to retain all of our future earnings, if any,
to finance the growth and development of our business. Any decision to declare and pay dividends in the future will be made at
the discretion of the Board and will depend on, among other things, our results of operations, financial condition, cash requirements,
contractual restrictions and other factors that the Board may deem relevant. In addition, our ability to pay dividends may be limited
by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur.
Liquidation, Dissolution and Winding Up
In
the event of our voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the Common Stock
will be entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders,
after the rights of the holders of the preferred stock have been satisfied.
Preemptive or Other Rights
Our
stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to Common
Stock.
Election of Directors
The
Bylaws provide that our business and affairs be managed by the Board. Our Board is composed of a single class of five directors, each
of whom will generally serve for a term of one year. There is no cumulative voting with respect to the election of directors, with the
result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors.
DESCRIPTION OF PREFERRED STOCK
The
following is a description of certain general terms and provisions of our preferred stock. The particular terms of any series of preferred
stock offered by us will be described in a prospectus supplement relating to such offering. The following description of our preferred
stock does not purport to be complete and is subject in all respects to applicable Delaware law and qualified by reference to the provisions
of our Certificate of Incorporation, Bylaws and the certificate of designation relating to each series of our preferred stock, which will
be filed with the SEC at or prior to the time of issuance of such series of preferred stock.
Our
Certificate of Incorporation authorizes our Board to issue, without further stockholder approval, up to 10,000,000 shares of preferred
stock in one or more series, having a par value of $0.0001 per share. As of the date of this prospectus, no shares of our preferred stock
were outstanding.
Our
Board is authorized to fix the designation and relative rights for each series of preferred stock, and the applicable prospectus supplement
will set forth with respect to such series, the following information:
| · | any stated redemption and liquidation values or preference per share; |
| · | any sinking fund provisions; |
| · | any conversion or exchange provisions; |
| · | any participation rights; |
| · | the terms of any other preferences, limitations and restrictions, as are stated in the resolutions adopted
by our Board and as are permitted by the Delaware General Corporation Law (the “DGCL”). |
The
transfer agent and registrar for each series of preferred stock will be described in the applicable prospectus supplement.
DESCRIPTION OF DEBT SECURITIES
The
debt securities may be senior debt securities or subordinated debt securities. The senior debt securities and the subordinated debt securities
are together referred to in this prospectus as the “debt securities.” The form of indenture is filed as an exhibit to the
registration statement of which this prospectus forms a part. We will include in a supplement to this prospectus the specific terms of
each series of debt securities being offered. The statements and descriptions in this prospectus or in any prospectus supplement regarding
provisions of the debt securities and the indenture are summaries thereof, do not purport to be complete and are subject to, and are qualified
in their entirety by reference to, all of the provisions of the indenture (and any amendments or supplements we may enter into from time
to time which are permitted under such indenture) and the debt securities, including the definitions therein of certain terms.
The
debt securities will not be guaranteed by any of our subsidiaries. The indenture does not
limit the aggregate principal amount of debt securities that we may issue and provides that we may issue debt securities from time to
time in one or more series, in each case with the same or various maturities, at par or at a discount. Unless indicated in a prospectus
supplement, we may issue additional debt securities of a particular series without the consent of the holders of the debt securities
of such series outstanding at the time of the issuance. Any such additional debt securities, together with all other outstanding debt
securities of that series, will constitute a single series of debt securities under the indenture.
We
will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered the aggregate principal amount and the following terms of the debt securities, if applicable:
| · | the title and ranking of the debt securities (including the terms of any subordination provisions); |
| · | the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; |
| · | covenants that we will adhere to in connection with the issuance and maintenance of debt securities; |
| · | events of default, acceleration, waivers of default, and related remedies, rights, and duties; |
| · | form, denomination, issuance, registration, transfer, and replacement of debt securities; |
| · | any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture
as it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection
with the marketing of the securities; and |
| · | satisfaction and discharge of debt securities. |
We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.
DESCRIPTION OF WARRANTS
A
warrant is a security that gives the holder the right, upon exercise of the warrant, to purchase a specified number of securities at a
specified exercise price, during a specified exercise period, which is subject to adjustment upon the occurrence of specified events.
We may issue warrants for the purchase of our common stock, preferred stock or debt securities or any combination thereof. Warrants may
be issued independently or together with our common stock, preferred stock or debt securities and may be attached to or separate from
any such offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and
a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the warrants. The warrant
agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. Warrants
will be offered and exercisable for United States dollars only. Warrants will be issued in registered form only. The particular terms
of any warrants will be described in the related prospectus supplement.
Anti-Takeover
Effects of CERTAIN Provisions of Delaware Law and
Our Certificate of Incorporation and Bylaws
Certain
provisions of the Certificate of Incorporation and Bylaws could have an anti-takeover effect. These provisions are intended to enhance
the likelihood of continuity and stability in the composition of the Board and in the policies formulated by the Board and to discourage
an unsolicited takeover of us if the Board determines that such takeover is not in the best interests of us and our stockholders. However,
these provisions could have the effect of discouraging certain attempts to acquire us or remove incumbent management even if some or a
majority of stockholders deemed such an attempt to be in their best interests.
The
provisions in the Certificate of Incorporation and the Bylaws include: (a) allowing only our board of directors to fill vacant directorships,
including newly created seats; (b) a requirement that special meetings of our stockholders may be called only by a majority of our board
of directors, the chairperson of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder
from calling a special meeting; (c) advance notice procedures for stockholders seeking to bring business before our annual meeting of
stockholders or to nominate candidates for election as directors at our annual meeting of stockholders; (d) the authority of the
Board to issue additional shares of common stock and/or preferred stock without stockholder approval; (e) that the number of directors
on the Board will be fixed exclusively by our Board; and (f) that our Bylaws may be amended by our Board.
The
DGCL contains statutory “anti-takeover” provisions, including Section 203 of the DGCL which applies automatically to
a Delaware corporation unless that corporation elects to opt-out as provided in Section 203. We, as a Delaware corporation, have
not elected to opt-out of Section 203 of the DGCL. Under Section 203 of the DGCL, a stockholder acquiring more than 15% of the
outstanding voting shares of a corporation (an “Interested Stockholder”) but less than 85% of such shares may not engage in
certain business combinations with the corporation for a period of three years subsequent to the date on which the stockholder became
an Interested Stockholder unless prior to such date, the board of directors of the corporation approves either the business combination
or the transaction which resulted in the stockholder becoming an Interested Stockholder, or the business combination is approved by the
board of directors and by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned
by the Interested Stockholder.
Limitation of Liability and Indemnification of Officers and Directors
Pursuant
to provisions of the DGCL, we have adopted provisions in our Certificate of Incorporation that provide that our directors shall not be
personally liable for monetary damages to us or our stockholders for a breach of fiduciary duty as a director to the full extent that
the Securities Act permits the limitation or elimination of the liability of directors.
We
have in effect a directors and officers liability insurance policy indemnifying our directors and officers and the directors and officers
of our subsidiaries within a specific limit for certain liabilities incurred by them, including liabilities under the Securities Act.
We pay the entire premium of this policy. Our Certificate of Incorporation also contains a provision for the indemnification by us of
all of our directors and officers, to the fullest extent permitted by the DGCL.
Exclusive Forum
Our
Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware
shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on
behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, other employee or
stockholder of the Company to the Company or the Company’s stockholders, (c) any action asserting a claim arising pursuant to any
provision of the DGCL, the Certificate of Incorporation, or Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery
of the State of Delaware, (d) any action to interpret, apply, enforce, or determine the validity
of our Certificate of Incorporation or Bylaws, or (e) any action asserting a claim governed by the internal affairs doctrine or
an “internal corporate claim” as that term is defined in Section 115 of the DGCL. If the Court of Chancery of the State
of Delaware does not have jurisdiction over a matter listed foregoing, the exclusive jurisdiction thereof shall be a state court located
within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court
for the District of Delaware). Any person or entity purchasing or otherwise acquiring any interest in shares of our stock shall be deemed
to have notice of and consented to the foregoing forum selection provisions.
SELLING SECURITYHOLDERS
This prospectus also relates
to the possible resale by certain of our stockholders, who we refer to in this prospectus as the “selling securityholders,”
of up to 3,000,000 shares of our common stock that were issued and outstanding prior to the original date of filing of the registration
statement of which this prospectus forms a part. Certain of the selling securityholders acquired shares of our common stock from Maui
Holdings, LLC, by virtue of Maui Holdings, LLC distributing all of the shares of the Company’s common stock owned by Maui Holdings,
LLC to its respective members, pro rata, based on their ownership of Maui Holdings, LLC and in accordance with the limited liability company
operating agreement thereof. The other remaining selling securityholders acquired shares of our common stock in private offerings pursuant
to exemptions from registration under Section 4(a)(2) of the Securities Act.
Information about the
selling securityholders, where applicable, including their identities, the amount of shares of common stock owned by each selling securityholder
prior to the offering, the number of shares of our common stock to be offered by each selling securityholder and the amount of common
stock to be owned by each selling securityholder after completion of the offering, will be set forth in an applicable prospectus supplement,
documents incorporated by reference or in a free writing prospectus we file with the SEC. The applicable prospectus supplement will also
disclose whether any of the selling securityholders have held any position or office with, have been employed by or otherwise have had
a material relationship with us during the three years prior to the date of the prospectus supplement.
The selling securityholders
may not sell any shares of our common stock pursuant to this prospectus until we have identified such selling securityholders and the
shares being offered for resale by such selling securityholders in a subsequent prospectus supplement. However, the selling securityholders
may sell or transfer all or a portion of their shares of our common stock pursuant to any available exemption from the registration requirements
of the Securities Act.
PLAN OF DISTRIBUTION
We
or any of the selling securityholders may sell securities in any one or more of the following ways (or in any combination) from time to
time:
| · | to or through one or more underwriters or dealers; |
| · | directly to a limited number of purchasers or to a single purchaser, including through a specific bidding,
auction or other process; or |
| · | through agents, brokers or dealers. |
The
applicable prospectus supplement will set forth the terms of the offering of such securities that we or any of the selling securityholders
sell, including:
| · | the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or
purchased by each of them; |
| · | the public offering price of the securities and the proceeds to us or any of the selling securityholders,
as applicable, and any discounts, commissions or concessions allowed or reallowed or paid to dealers; |
| · | describing any compensation in the form of discounts, concessions or commissions or otherwise received
from us or any of the selling securityholders by each of such underwriter, dealer or agent and in the aggregate to all underwriters, dealers
and agents; |
| · | identifying the amounts underwritten; |
| · | identifying the nature of the underwriter’s obligation to take the securities; |
| · | identifying any over-allotment option under which the underwriters may purchase additional securities
from us or any of the selling securityholders; |
| · | identifying any quotation systems or securities exchanges on which the securities may be quoted or listed;
and |
| · | identifying any other facts material to the transaction. |
Any
public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
We
or any of the selling securityholders may effect the distribution of the securities from time to time in one or more transactions either:
| · | at a fixed price or at prices that may be changed; |
| · | at market prices prevailing at the time of sale; |
| · | at prices relating to such prevailing market prices; or |
Any
underwritten offering may be on a best efforts or a firm commitment basis. If underwriters are used in the sale of any securities, the
securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
including, without limitation, negotiated transactions, at a fixed public offering price or at varying prices determined at the time of
sale. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly
by underwriters without a syndicate. Generally, the underwriters’ obligations, if any, to purchase the securities will be subject
to certain conditions precedent. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities if
they purchase any of the securities (other than any securities purchased upon exercise of any option to purchase additional securities
or any over-allotment option). Any public offering price and any discounts or concessions allowed, reallowed or paid to dealers may be
changed from time to time.
If
a dealer is used in an offering of securities, we or the selling securityholders may sell the securities to the dealer, as principal.
The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of sale. The prospectus
supplement may set forth the name of the dealer and the terms of the transactions.
We
or the selling securityholders may sell the securities directly or through agents, underwriters and dealers that we or any of the
selling securityholders designate from time to time. The applicable prospectus supplement will name any agent, underwriter or dealer
involved in the offer or sale of the securities and will describe any commissions payable by us or any of the selling
securityholders to the agent. Generally, any agent, underwriter or dealer will be acting on a best efforts basis for the period of
its appointment.
We
may also sell the securities offered by any applicable prospectus supplement in “at-the-market offerings” within the meaning
of Rule 415 of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise. If a
broker is used in the sale of the securities, the broker will not acquire the securities, and we will sell the securities directly to
the purchasers in the applicable market. The prospectus supplement will set forth the terms of the arrangements with the broker.
We
or any of the selling securityholders may sell the securities directly to one or more purchasers without using any underwriters, dealers
or agents. In that event, no underwriters or agents would be involved. In addition, we or any of the selling securityholders may enter
into derivative, sale or forward sale transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third
parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the
applicable prospectus supplement. If so, a third party may use securities borrowed from us or any of the selling securityholders to settle
such sales and may use securities received from us or others to settle those sales to close out any related short positions. The third
party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective
amendment). We or any of the selling securityholders may also loan or pledge securities covered by this prospectus and the applicable
prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the
pledged securities pursuant to this prospectus and the applicable prospectus supplement. We or any of the selling securityholders may
also sell the securities directly, in which event, no underwriters or agents will be involved.
In
the sale of the securities, underwriters, dealers or agents may receive compensation in the form of commissions, discounts or concessions
from us or any of the selling securityholders. Underwriters, dealers or agents may also receive compensation from the purchasers of securities
for whom they act as agents or to whom they sell as principals, or both. Any underwriters, broker-dealers and agents that participate
in the distribution of the securities may be deemed to be “underwriters” as defined in the Securities Act. Any commissions
paid or any discounts or concessions allowed to any such persons, and any profits they receive on resale of the securities, may be deemed
to be underwriting discounts and commissions under the Securities Act. Compensation as to a particular underwriter, dealer or agent might
be in excess of customary commissions and will be in amounts to be negotiated in connection with transactions involving securities. In
effecting sales, broker-dealers engaged by us may arrange for other broker-dealers to participate in the resales. Maximum compensation
to any underwriters, brokers, dealers or agents will not exceed any applicable FINRA limitations.
Agents,
underwriters and dealers may be entitled under relevant agreements with us or to indemnification by us against certain liabilities,
including liabilities under the Securities Act, or to contribution with respect to payments which such agents, underwriters and dealers
may be required to make in respect thereof. The terms and conditions of any indemnification or contribution will be described in
the applicable prospectus supplement.
Underwriters
or agents may purchase and sell the securities in the open market. These transactions may include over-allotments, stabilizing transactions,
syndicate covering transactions and penalty bids. Over-allotments involve sales in excess of the offering size, which creates a short
position. Stabilizing transactions consist of bids or purchases for the purpose of preventing or retarding a decline in the market price
of the securities and are permitted so long as the stabilizing bids do not exceed a specified maximum. Syndicate covering transactions
involve the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created
in connection with an offering. The underwriters or agents also may impose a penalty bid, which permits them to reclaim selling concessions
allowed to syndicate members or certain dealers if they repurchase the securities in stabilizing or covering transactions. These activities
may stabilize, maintain or otherwise affect the market price of the securities, which may be higher than the price that might otherwise
prevail in the open market. These activities, if begun, may be discontinued at any time. These transactions may be effected on any exchange
on which the securities are traded, in the over-the-counter market or otherwise.
Agents,
dealers and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.
The
specific terms of any lock-up provisions in respect of any given offering of common stock will be described in the applicable prospectus
supplement.
The
place and time of delivery for securities will be set forth in the accompanying prospectus supplement for such securities. To comply with
applicable state securities laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through
registered or licensed brokers or dealers. In addition, securities may not be sold in some states unless they have been registered or
qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied
with.
Unless
otherwise specified in the related prospectus supplement, each series of securities that we sell will be a new issue with no established
trading market, other than the common stock, which is listed on the New York Stock Exchange. Any common stock sold pursuant to a prospectus
supplement will be listed on the New York Stock Exchange, subject to applicable notices. We may elect to apply for quotation or listing
of any other class or series of our securities on a quotation system or an exchange but we are not obligated to do so. It is possible
that one or more underwriters may make a market in a class or series of our securities, but such underwriters will not be obligated to
do so and may discontinue any market making at any time without notice. Any such activities will be described in the prospectus supplement.
Therefore, no assurance can be given as to the liquidity of, or the trading market for, any other class or series of our securities.
WHERE YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC’s website at www.sec.gov. Copies of certain information filed by us with the SEC
are also available on our website at www.cadre-holdings.com. Information accessible on or through our website is not a part of this
prospectus (other than the documents that we file with the SEC that are expressly incorporated by reference into this prospectus).
This
prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the
information in the registration statement. You should review the information and exhibits in the registration statement for further information
on us and our consolidated subsidiaries and the securities that we are offering. Forms of any indenture or other documents establishing
the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under
cover of a Current Report on Form 8-K and incorporated in this prospectus by reference. Statements in this prospectus or any
prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document
to which it refers. You should read the actual documents for a more complete description of the relevant matters.
This
prospectus omits certain information that is contained in the registration statement on file with the SEC, of which this prospectus is
a part. For further information with respect to us and our securities, reference is made to the registration statement, including the
exhibits incorporated therein by reference or filed therewith. Statements herein contained concerning the provisions of any document are
not necessarily complete and, in each instance, reference is made to the copy of such document filed as an exhibit or incorporated by
reference to the registration statement. Each such statement is qualified in its entirety by such reference.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information
in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part
the information or documents listed below that we have filed with the SEC (Commission File No. 001-40698):
| · | our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 15, 2023; |
| · | our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on
May 9, 2023; |
| · | our
information specifically incorporated by reference into our Annual Report on Form 10-K for
the year ended December 31, 2022 from our Definitive Proxy Statement on Schedule 14A filed
with the SEC on April 21, 2023; and |
| · | the description of our common stock contained in our Registration Statement on Form 8-A12B, filed with
the SEC on October 29, 2021 under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), including, without
limitation, any amendment or report filed for the purpose of updating such description. |
We
also incorporate by reference any future filings (other than any filings or portions of such reports that are not deemed “filed”
under the Exchange Act in accordance with the Exchange Act and applicable SEC rules, including current reports furnished under Item 2.02
or Item 7.01 of Form 8-K and exhibits furnished on such form that are related to such items unless such Form 8-K expressly provides to
the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date on which
the registration statement that includes this prospectus was initially filed with the SEC (including all such documents we may file with
the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement) and until
we file a post-effective amendment which indicates the termination of the offering of the securities made by this prospectus and the
accompanying prospectus supplement shall be deemed to be incorporated by reference into this prospectus and to be part hereof from the
date of filing of those documents. Information in such future filings updates and supplements the information provided in this prospectus
and the accompanying prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede
any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference
to the extent that statements in the later filed document modify or replace such earlier statements.
You
may obtain copies of any of these filings by contacting us at the address and telephone number indicated below.
Documents
incorporated by reference are available from us without charge, excluding all exhibits unless an exhibit has been specifically incorporated
by reference into this prospectus, by requesting them in writing or by telephone at:
Cadre Holdings, Inc.
Attention: Corporate Secretary
13386 International Pkwy
Jacksonville, Florida 32218
(904) 741-5400
EXPERTS
The
consolidated financial statements of Cadre Holdings, Inc. as of December 31, 2022 and 2021, and for the years then ended, have been incorporated
by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting
firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
LEGAL MATTERS
The
validity of the securities offered hereby by or on behalf of the Company will be passed upon for us by Kane Kessler, P.C., New York, New
York. Additional legal matters may be passed upon for us, the selling securityholders or any underwriters, dealers or agents, by counsel
that we will name in the applicable prospectus supplement.
Robert
L. Lawrence, Esq., a member of Kane Kessler, P.C., owns 81,167 shares of the Company’s common
stock.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The
expenses to be paid by us in connection with the distribution of securities of Cadre Holdings, Inc. (the “Registrant”) being
registered are as set forth in the following table:
| Registration Fee - Securities and Exchange Commission |
|
$ |
40,462.13 |
|
| Legal Fees and Expenses |
|
|
* |
|
| Accounting Fees and Expenses |
|
|
* |
|
| Printing and Engraving Fees and Expenses |
|
|
* |
|
| Blue Sky Fees |
|
|
* |
|
| Miscellaneous |
|
|
* |
|
| Total |
|
$ |
40,462.13 |
|
| * | The foregoing sets forth the general categories of fees and expenses (other than underwriting discounts and commissions) that we anticipate
we will incur in connection with the offering of securities under this registration statement. Because an indeterminate amount of securities
is covered by this registration statement, certain expenses in connection with the issuance and distribution of securities are not currently
determinable. An estimate of the aggregate fees and expenses in connection with each sale of securities being offered will be included
in the applicable prospectus supplement. |
Item 15. Indemnification of Directors and Officers
Section 145(a)
of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and
in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
Section 145(b)
of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because
the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such
action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she
shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating
court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly
and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.
Section 145(g)
of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person
and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have
the power to indemnify the person against such liability under Section 145 of the DGCL.
The
Registrant’s Certificate of Incorporation limits the Registrant’s directors’ and officers’ liability to the fullest
extent permitted under the DGCL and other applicable laws.
The
Registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that
the registrant will indemnify each of its directors and such officers to the fullest extent permitted by law and its charter and its bylaws.
The
Registrant also maintains a general liability insurance policy, which will cover certain liabilities of directors and officers of the
registrant arising out of claims based on acts or omissions in their capacities as directors or officers.
Item 16. Exhibits and Financial Statement Schedules
The
following exhibits are included herein or incorporated by reference:
| (1) | To be filed, if necessary, by post-effective amendment to this Registration Statement or incorporated
by reference from documents filed or to be filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. |
| (3) | To be filed separately pursuant to the requirements of Section 305(b)(2) of the Trust Indenture Act of
1939, as amended |
Item 17. Undertakings
| (a) | The undersigned registrant hereby undertakes: |
| (1) | to file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: |
| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set
forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
| (iii) | to include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement; |
provided, however, that paragraphs
(a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by
those subsections is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of
prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| (2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) | To remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering. |
| (4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
| (i) | each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of this
registration statement as of the date the filed prospectus was deemed part of and included in this registration statement; and |
| (ii) | each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing
the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of
sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating
to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof, provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date. |
| (5) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any
purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities
of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned
registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
| (i) | any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424; |
| (ii) | any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant
or used or referred to by the undersigned registrant; |
| (iii) | the portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
| (iv) | any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
| (b) | The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act of 1933, each filing of the registrant’s Annual Report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in the registration statement shall be deemed to be a new registration statement
relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. |
| (c) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding), is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act of 1933 and will be governed by the final adjudication of such issue. |
| (d) | The undersigned registrant hereby undertakes to file an application for the purpose of to file, if applicable,
an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture
Act of 1939 (the “Act”) in accordance with the rules and regulations prescribed by the SEC under Section 305(b)(2) of the
Act. |
SIGNATURES
Pursuant to the requirements
of the Securities Act, the undersigned registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this Amendment No. 1 to this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Jacksonville, State of Florida, on May 16, 2023.
| |
CADRE HOLDINGS, INC. |
| |
|
| |
By: |
/s/ Warren B. Kanders |
| |
|
Name: |
Warren B. Kanders |
| |
|
Title: |
Chief Executive Officer |
Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and
on the dates indicated:
| Signature |
|
Title |
|
Date |
| |
|
|
|
|
| * |
|
Chief
Executive Officer and Chairman |
|
May 16, 2023 |
| Warren
B. Kanders |
|
(Principal
Executive Officer) |
|
|
| |
|
|
|
|
| * |
|
President |
|
May 16, 2023 |
| Brad Williams |
|
|
|
|
| |
|
|
|
|
| /s/
Blaine Browers |
|
Chief
Financial Officer |
|
May 16, 2023 |
| Blaine Browers |
|
(Principal Financial
Officer and Principal Accounting Officer) |
|
|
| |
|
|
|
|
| * |
|
Director |
|
May 16, 2023 |
| Hamish
Norton |
|
|
|
|
| |
|
|
|
|
| * |
|
Director |
|
May 16, 2023 |
| Nicholas
Sokolow |
|
|
|
|
| |
|
|
|
|
| * |
|
Director |
|
May 16, 2023 |
| William
Quigley |
|
|
|
|
| |
|
|
|
|
| * |
|
Director |
|
May 16, 2023 |
| Deborah
A. DeCotis |
|
|
|
|
| * By: |
/s/ Blaine Browers |
|
| |
Name: Blaine Browers |
|
| |
Title: Attorney-in-Fact |
|
Cadre (NYSE:CDRE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Cadre (NYSE:CDRE)
Historical Stock Chart
From Jan 2024 to Jan 2025
